What is Prostamax 20MG

Prostamax 20MG is a synthetic tetrapeptide bioregulator studied in research for its highly targeted effects on prostate gland function, male reproductive health, and urinary tract integrity. It is intended exclusively for research use.

Regarding its chemical identity, Prostamax has a molecular formula of C17H32N8O9 and a molecular weight of 492.5 g/mol. Its reported canonical sequence is Lys-Glu-Asp-Pro. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Prostamax.

Product for research use.

Mechanism of action of Prostamax

Prostamax interacts specifically with the DNA of prostate cells to regulate the expression of proteins involved in glandular function. It reduces chronic inflammation, normalizes the secretory function of the prostate, and prevents the pathological proliferation of prostate tissue.

Pharmacokinetics and pharmacodynamics of Prostamax

Characterized by an extremely rapid half-life. It acts quickly to initiate epigenetic modifications within the prostate, producing long-lasting regulatory and anti-inflammatory effects after the peptide itself has been degraded.

Scientific evidence on Prostamax

The available evidence on Prostamax is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated heavily in preclinical models of benign prostatic hyperplasia (BPH) and chronic prostatitis. Evidence suggests it helps restore normal urine flow, reduces prostate volume, and improves the overall quality of seminal fluid.

Prostamax applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Prostamax protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Prostamax, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Prostamax

As a general guideline for laboratory handling, lyophilized peptides such as Prostamax are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Prostamax Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Prostamax security profile

The documented safety information in open sources for Prostamax is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting the prostate, it has a favorable theoretical safety profile. Since it acts as a homeostatic bioregulator rather than an endocrine disruptor, it does not alter systemic testosterone or estrogen levels, avoiding the side effects of traditional BPH drugs.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Prostamax in a comparative context

Prostamax is the synthetic analogue of the natural prostate extract Libidon. Unlike 5-alpha-reductase inhibitors (like Finasteride) which forcefully block DHT conversion, Prostamax restores cellular health at the genetic level without causing sexual dysfunction.

History and development of Prostamax

Developed by the Khavinson group in Russia to address the widespread issue of age-related prostate decline. It was synthesized based on the analysis of active signaling peptides in healthy animal prostates.